Introduction
The Kerala Model of healthcare — built on high life expectancy, low infant mortality, and affordable treatment — is facing a structural stress test as global private equity reshapes its hospital landscape.
"A large number of people seeking medical treatment and their willingness to pay could be driving large private equity firms to Kerala." — Dr. A. Althaf, Professor of Community Medicine, GMC Thiruvananthapuram
| Indicator | Figure |
|---|---|
| PE Investment in Kerala Hospitals (recent years) | ₹5,800+ crore |
| Per Capita Private Health Expenditure (2013-14) | ₹7,636 |
| Per Capita Private Health Expenditure (2021-22) | ₹13,343 |
| Private Share of Total Health Expenditure (2021-22) | 59.1% |
Background: The Kerala Model and Its Foundations
Kerala achieved health outcomes comparable to developed nations — life expectancy ~75 years, infant mortality rate of 5 per 1,000 live births (2024) — through a unique combination of:
- Extensive public health infrastructure
- High health literacy and hygiene awareness
- Strong network of small private, cooperative, and charitable hospitals
- Relatively affordable out-of-pocket expenditure
This model succeeded not because of corporate hospitals, but despite their absence — through decentralised, community-level care delivery.
The Corporatisation Wave: Key Data Points
| Transaction | Year | Investor | Amount |
|---|---|---|---|
| KKR acquires 70% stake in Baby Memorial Hospital (BMH), Kozhikode | 2024 | KKR (USA) | ₹2,500 crore |
| Blackstone-backed Quality Care acquires 80% of KIMS Health | 2023 | Blackstone (USA) | ₹3,300 crore |
| Aster DM Healthcare India merges with Quality Care | 2024 | Blackstone | Undisclosed |
| BMH acquires majority stake in Meitra Hospital, Kozhikode | 2025 | KKR (via BMH) | Undisclosed |
| CCI clears Bentley Asia Holdings' additional stake in BMH | March 2026 | Bentley Asia/KKR | Undisclosed |
Corporate hospitals (500+ beds) have grown by at least 65% in the past 10 years in Kerala.
The Other Side: Disappearing Small Hospitals
While large hospitals expand, small private hospitals — the backbone of rural and semi-urban affordable care — are shutting down.
| Period | OP Institutions Closed | IP Institutions Closed |
|---|---|---|
| 2016–2021 | 148 | 262 |
| 2021–2026 | 1,306 | 444 |
Despite closure of small institutions, overall bed count in Kerala rose only marginally — from 80,267 to 82,557 between 2021 and 2026 — indicating that corporate expansion has not compensated for the loss of distributed, affordable care.
Primary cause of closures: Strict enforcement of the Clinical Establishments (Registration and Regulation) Act, 2018 — compliance costs disproportionately burden small operators while large corporates absorb them easily.
Key Analytical Issues
1. Out-of-Pocket Expenditure (OOPE) and Equity
- Private health expenditure share: 76% (2013-14) → 59.1% (2021-22) — a decline, but still high.
- Government share rose from 24% to 32.5% — reflecting increased public investment.
- Yet absolute OOPE per capita nearly doubled in the same period — affordability stress is real.
"A large number of people seeking medical treatment and their willingness to pay could be driving large private equity firms to Kerala." — Dr. A. Althaf, Professor of Community Medicine, GMC Thiruvananthapuram
2. Revenue Targets and Clinical Autonomy
Corporate hospitals impose revenue-linked targets on specialist doctors — quotas for admissions, diagnostic tests, and procedures. This creates perverse incentives:
- Over-investigation and over-treatment
- Erosion of doctor-patient trust
- Rise in violence against healthcare workers
A UN University–International Institute for Global Health (2025) background paper flagged that corporatisation introduces managerial oversight driven by business principles, limiting professional medical autonomy.
3. The Insurance Trap
Corporate expansion is closely tied to health insurance growth. Critics argue this creates an insurance-dependent model where:
- Uninsured patients face denial of care or prohibitive costs
- Hospitals optimise for insured patients with higher billing potential
- Government schemes (like Ayushman Bharat, Karunya Arogya Suraksha Padhathi) become captured by corporate billing practices
4. Elimination of General Practitioners (GPs)
The corporate model favours specialists over family doctors. Kerala's traditional strength — accessible primary care through GPs — is being dismantled, pushing even minor ailments into expensive specialist and tertiary settings.
"Family doctors or general practitioners are the most important doctors in the community for providing primary care. However, they have been eliminated." — Dr. P.K. Sasidharan, Former HoD General Medicine, GMC Kozhikode
Government Response
- Chief Minister flagged rising private healthcare costs publicly — signalling political awareness but limited regulatory action so far.
- Health Minister emphasised strengthening government hospitals with free/subsidised treatment and warned against deliberate patient diversion to corporate hospitals.
- Kerala's Medisep scheme (health insurance for government employees) and KASP (Karunya Arogya Suraksha Padhathi) are attempts to insulate vulnerable populations from OOPE.
Industry Counter-Argument
Harish Manian (Group CEO, BMH) argues:
- Private investment represents adaptation, not commercialisation
- Average Revenue Per Occupied Bed (ARPOB) in Kerala remains the lowest in India despite PE investment
- Scale improves procurement efficiency, governance, and long-term planning
- Healthcare financing will remain hybrid — combining government schemes, insurance, and self-pay
This perspective deserves engagement — not all PE investment leads to price escalation, and governance quality, not capital source, is the real determinant.
Comparison: Corporatisation Models
| Dimension | Kerala (Emerging) | US Model | Thailand Model |
|---|---|---|---|
| Primary Driver | PE consolidation | Insurance-linked corporates | Public-private partnership |
| OOPE Level | High but declining | Very high | Low |
| Access for Poor | Strained | Severely limited | Protected via UHC |
| Regulatory Framework | Weak enforcement | Strong antitrust | Strong public oversight |
| Outcome | Model under stress | High cost, unequal | High quality, equitable |
Implications and Challenges
- Equity erosion: Consolidation concentrates quality care among the affluent and insured, leaving the poor dependent on underfunded public facilities.
- Regulatory vacuum: India lacks a comprehensive law to regulate pricing, clinical standards, and PE participation in healthcare — the Clinical Establishments Act is inadequate.
- NCD burden: Rising diabetes, hypertension, cancers, and mental health issues increase demand for expensive specialist care — a structural driver of corporatisation that public health alone cannot address.
- Ageing population: Kerala's demographic profile — one of India's oldest populations — will sustain demand for costly geriatric and long-term care, further incentivising PE entry.
- CCI's limited role: Competition Commission approvals focus on market dominance, not healthcare equity — a critical gap in regulatory architecture.
Conclusion
Kerala's healthcare paradox — world-class indicators coexisting with rising costs and declining access — is a warning sign for India's broader health governance debate. Private equity investment is not inherently harmful; but without robust regulatory architecture, transparent pricing norms, and a strengthened public health system, corporatisation risks converting a public good into a market commodity. The solution lies not in rejecting private participation but in ensuring that governance, not profit, drives clinical decisions. Strengthening primary care, reviving the GP ecosystem, enforcing the Clinical Establishments Act equitably, and expanding universal health coverage are the policy imperatives — failing which the Kerala Model risks becoming a cautionary tale rather than a template.
